Contact Us

The choice depends on the experimental question, but for SLC38A12 — an emerging factor — the framing of the question itself often needs to come first. SLC38A12 belongs to the SLC38/SNAT family of sodium-coupled neutral amino acid transporters but is comparatively less characterized than SNAT1-5 and SNAT7. Predicted to function as an amino acid transporter, but the substrate specificity, sodium-coupling, and cellular function require empirical determination. The EDITGENE Knockout in HCT 116 is most useful for unbiased discovery — characterizing transcriptomic and metabolomic consequences of SLC38A12 loss in a colorectal cancer background to identify candidate substrates and functions. Discovery-oriented approaches (metabolomics with broad amino acid panel, transcriptomics) in the knockout are most informative at this stage. Rescue with wild-type SLC38A12 serves as the specificity control during phenotypic characterization.

Yes, and rescue experiments are particularly important for this under-characterized factor: • Construct design: use a codon-modified SLC38A12 sequence with a small C-terminal tag (FLAG, HA). The predicted SLC38 family transmembrane architecture should be preserved. • Discovery-oriented rescue: parallel wild-type rescue during phenotypic characterization distinguishes true SLC38A12-dependent phenotypes from off-target editing artifacts — critical for emerging factors. • Localization validation: confirm subcellular localization of exogenous protein by imaging given limited prior data. • Functional readout: rescue should restore phenotypes identified in discovery transcriptomics or metabolomics analyses; amino acid uptake panels test the predicted SLC38 family activity. HCT 116 transduces efficiently with lentivirus and supports stable rescue line generation.

The choice depends on whether you are studying SLC3A2 (4F2hc/CD98)'s role as the heavy chain partner for heterodimeric amino acid transporters or its functions in integrin signaling and cancer biology. The Knockout line is the standard tool for asking whether 4F2hc is required for surface expression and function of LAT1, LAT2, xCT, and other heterodimeric SLC7 family transporters — 4F2hc partnership is essential for these transporters' membrane localization and stability. Overexpression is useful for studying CD98's reported role in integrin clustering and signaling, distinct from its transporter chaperone function. For amino acid transporter research, the EDITGENE 4F2hc Knockout in A-549 is highly informative because 4F2hc loss simultaneously disrupts multiple heterodimeric transporters (LAT1, LAT2, xCT, asc-1, y+LAT1, y+LAT2). A-549 expresses LAT1 and xCT, making this lung cancer background relevant for studying amino acid transporter pharmacology in NSCLC. Rescue with wild-type or signaling-deficient 4F2hc separates transporter chaperone from integrin-related functions.

Yes. 4F2hc rescue experiments require attention to its dual chaperone/signaling functions: • Construct design: use a codon-modified SLC3A2 sequence with a small C-terminal cytoplasmic tag (FLAG, HA). 4F2hc is a type II membrane protein — preserve the disulfide-linked extracellular domain that mediates SLC7 partner interactions. • Cytoplasmic tail-deleted rescue: cytoplasmic tail deletion separates SLC7 transporter chaperone function from integrin signaling roles — critical for distinguishing these dual functions. • Disulfide bond mutant rescue: cysteine mutations affecting heterodimer formation with SLC7 partners enable assessment of transporter-related functions specifically. • Functional readout: rescue should restore surface expression of LAT1, LAT2, xCT, and other SLC7 partners (assessed by cell surface biotinylation) and downstream amino acid uptake activities. A-549 transduces efficiently with lentivirus and supports stable rescue line generation.

The choice depends on whether you are studying SYNCRIP's role as an hnRNP family RNA-binding protein or its emerging functions in mRNA stability, alternative splicing, and cancer biology. The Knockout line is appropriate for asking whether SYNCRIP is required for specific mRNA stability programs or splicing events. Overexpression is useful for testing whether elevated SYNCRIP is sufficient to alter target transcript abundance. For SYNCRIP research, the EDITGENE Knockout in HCT 116 is particularly relevant given emerging evidence for SYNCRIP roles in colorectal cancer biology, including m6A reader activity for certain mRNA classes. The HCT 116 MSI-high background also provides context for studying SYNCRIP in mismatch repair-deficient colorectal cancer. Rescue with wild-type or RNA-binding-deficient (KH/RRM domain mutant) SYNCRIP enables structure-function dissection.

Yes. SYNCRIP rescue experiments require attention to its RNA-binding architecture: • Construct design: use a codon-modified SYNCRIP sequence with a C-terminal tag (FLAG, HA). SYNCRIP contains three KH domains and an additional RBD; all RNA-binding modules should be preserved. • RNA-binding-deficient rescue: KH domain GXXG-motif mutations abolish RNA binding and are the standard specificity control for distinguishing RNA-engagement-dependent functions. • Domain-specific rescue: selective inactivation of individual KH domains can identify which domains contribute to specific RNA target classes. • Functional readout: rescue should restore target mRNA stability, splicing patterns, and reported m6A reader activities for candidate transcripts. HCT 116 transduces efficiently with lentivirus and supports stable rescue line generation.

The choice depends on whether you are studying SNX3's role in retromer-mediated endosome-to-Golgi retrieval or its functions in Wnt secretion (Wntless trafficking). The Knockout line is the standard tool for asking whether SNX3 is required for these endosomal sorting events — particularly relevant in HCT 116 where Wnt pathway dysregulation is a feature of colorectal cancer biology. Overexpression is useful for testing SNX3 sufficiency in retromer cargo recruitment. For SNX3 research, the EDITGENE Knockout in HCT 116 provides a colorectal cancer-relevant context for studying retromer-dependent Wnt secretion — Wntless/GPR177 cycling through endosomes requires SNX3-retromer for proper trafficking. Rescue with wild-type or PX-domain-mutant SNX3 (phosphatidylinositol 3-phosphate-binding-deficient) enables endosomal membrane targeting versus cargo recognition dissection.

Yes. SNX3 rescue experiments require attention to phosphoinositide-dependent membrane targeting: • Construct design: use a codon-modified SNX3 sequence with a small C-terminal tag (FLAG, HA, GFP for imaging). SNX3 is small (~162 amino acids) and consists primarily of a PX domain. • PX domain-mutant rescue: PI3P-binding-deficient mutations (e.g., R57E) abolish endosomal membrane targeting and serve as the standard specificity control. • Cargo-binding-deficient rescue: where mapped, mutations affecting SNX3's interaction with retromer cargo (Wntless) enable functional dissection. • Functional readout: rescue should restore Wntless trafficking and Wnt secretion in HCT 116. HCT 116 transduces efficiently with lentivirus; the MSI-high colorectal cancer background should be considered when interpreting Wnt pathway readouts.

The choice depends on whether you are studying SLC31A2 (CTR2)'s role as an intracellular low-affinity copper transporter or its emerging functions in lysosomal copper handling. The Knockout line is appropriate for asking whether CTR2 is required for these activities — CTR2 is distinct from CTR1 (SLC31A1, the high-affinity plasma membrane copper importer) and functions primarily at endosomes/lysosomes. Overexpression is useful for studying CTR2 in heterologous expression systems or for assessing platinum chemotherapy resistance mechanisms. For copper biology research, the EDITGENE SLC31A2 Knockout in HCT 116 enables study of intracellular copper trafficking distinct from CTR1-mediated uptake. CTR2 is implicated in resistance to platinum-based chemotherapy (cisplatin, carboplatin) through reduced drug accumulation. Rescue with wild-type or transport-deficient CTR2 is the standard specificity control.

Yes. CTR2 rescue experiments require attention to intracellular targeting: • Construct design: use a codon-modified SLC31A2 sequence with a small C-terminal tag (FLAG, HA). CTR2 has 3 transmembrane domains and intracellular trafficking determinants. • Endosomal/lysosomal localization validation: confirm intracellular localization by LAMP1 or Rab9 co-staining — CTR2 functions primarily at endosomes/lysosomes. • Transport-deficient rescue: methionine-rich motif mutations enable structure-function studies of copper coordination. • Functional readout: rescue should restore intracellular copper handling and platinum chemotherapy sensitivity profiles. HCT 116 transduces efficiently with lentivirus and supports stable rescue line generation.

The choice depends on whether you are studying SLC29A2 (ENT2)'s role as an equilibrative nucleoside transporter or its contributions to nucleoside analog drug uptake. The Knockout line is the standard tool for asking whether ENT2 is required for nucleoside transport — ENT2 is broadly expressed and transports both purine and pyrimidine nucleosides as well as nucleobases. Overexpression is useful for testing nucleoside analog drug uptake or for distinguishing ENT2-specific functions from ENT1 (SLC29A1). For ENT2 research, the EDITGENE Knockout in HCT 116 is particularly relevant for studying nucleoside analog chemotherapy uptake (cytarabine/Ara-C, gemcitabine, fludarabine, cladribine) in a cancer cell context. ENT1 paralog expression analysis is important given functional overlap. ENT inhibitors (dipyridamole, NBMPR) specificity testing benefits from this knockout. Rescue with wild-type or transport-deficient ENT2 enables structure-function studies.

Yes. ENT2 rescue experiments are well-established for nucleoside transporter research: • Construct design: use a codon-modified SLC29A2 sequence with a small C-terminal tag (FLAG, HA). ENT2 has 11 transmembrane domains in the canonical ENT family architecture. • Transport-deficient rescue: substrate-binding pocket mutations enable structure-function studies. • Drug sensitivity rescue: nucleoside analog (cytarabine, gemcitabine) sensitivity restoration in ENT2-null cells confirms rescue functionality. • Functional readout: rescue should restore nucleoside uptake (³H-thymidine, ³H-uridine) and nucleoside analog drug sensitivity. HCT 116 transduces efficiently with lentivirus and supports stable rescue line generation.

The choice depends on whether you are studying SLC36A1 (PAT1)'s role as a proton-coupled amino acid transporter or its specific contributions to intestinal absorption of small amino acids and amino acid-like drugs. The Knockout line is the standard tool for asking whether PAT1 is required for proton-dependent uptake of glycine, proline, alanine, and γ-aminobutyric acid (GABA) — particularly relevant in HCT 116, which has intestinal epithelial origins. Overexpression is useful for testing transport activity in heterologous systems and for assessing drug-substrate interactions. For PAT1 research, the EDITGENE Knockout in HCT 116 is highly informative for intestinal amino acid absorption and oral drug bioavailability studies — PAT1 contributes to apical uptake of certain GABA-related drugs (vigabatrin, gabapentin analogs) and δ-aminolevulinic acid (5-ALA used in photodynamic therapy). Rescue with wild-type or transport-deficient PAT1 enables structure-function studies, and is a critical specificity control for PAT1-mediated drug uptake research.

Yes. PAT1 rescue experiments require attention to proton-coupling and pH-dependence: • Construct design: use a codon-modified SLC36A1 sequence with a small C-terminal tag (FLAG, HA). PAT1 has 11 transmembrane domains — N-terminal tags must not disrupt topology. • Transport-deficient rescue: conserved residue mutations in proton-binding sites or substrate-binding pockets enable structure-function studies. • pH-dependence: PAT1 transport is highly pH-sensitive — rescue assays should be performed under controlled extracellular pH conditions (typically pH 5.5-6.5 for optimal activity). • Functional readout: rescue should restore proton-coupled amino acid uptake measured by ³H-glycine or related substrate uptake. HCT 116 transduces efficiently with lentivirus and supports stable rescue line generation for intestinal-relevant transport studies.

The choice depends on whether you are studying SLC5A6 (SMVT)'s role in intestinal biotin and pantothenate uptake or its emerging functions in colorectal cancer drug delivery research. The Knockout line is the standard tool for asking whether SMVT is required for intestinal vitamin transport in an epithelial cancer context. Overexpression is useful for transport activity studies and for biotin-conjugate drug delivery research. For intestinal SMVT research, the EDITGENE Knockout in HCT 116 is particularly relevant — HCT 116 supports intestinal-relevant transport studies, and SMVT overexpression has been explored as a biotin-targeted drug delivery strategy in colorectal cancer. This product complements the parallel SLC5A6 Knockout in HEK293 (also available); HCT 116 is preferred for intestinal absorption biology and CRC drug development contexts. Rescue with wild-type or transport-deficient SMVT is the standard specificity control.